STVNN Stock Chart & Stats
$290.00
$0.00(0.00%)
At close: 4:00 PM EDT
$290.00
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$246.00 - $444.62
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
$99.39B
Enterprise Value$5.35B
Total Cash (Recent Filing)$83.58M
Total Debt (Recent Filing)$442.99M
Price to Earnings (P/E)36.1
Beta0.04
Next Earnings
Nov 03, 2026EPS Estimate
3.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.48
Shares Outstanding49,709,717
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio2.50
Price to Book (P/B)3.15
Price to Sales (P/S)4.10
P/FCF Ratio218.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$435.85Price Target Upside50.29% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
EPS Forecast (FY)11.32
Revenue Forecast (FY)$23.68B
Bulls Say, Bears Say
Bulls Say
High-value Solutions GrowthRapid growth in high-value solutions is improving Stevanato’s product mix and deepening its role in biologics and premium injectable therapies. A larger share of specialized offerings can support recurring customer relationships, stronger differentiation, and better long-term earnings quality.
Profitability And Margin ExpansionStrong adjusted EBITDA growth alongside material margin expansion indicates operating leverage and improving profitability in the current business mix. If sustained, higher margins should strengthen internal funding capacity and provide greater resilience as the company scales its specialized platforms.
Conservative Balance SheetModerate leverage and a growing equity base give Stevanato financial capacity to support expansion while limiting balance-sheet strain. This capitalization provides a useful buffer against execution volatility and leaves more flexibility for investment in plants, equipment, and product development.
Bears Say
Weak Free-cash-flow ConversionPositive operating cash flow is not currently translating into free cash flow because capital spending and working-capital needs are absorbing cash. Persistent volatility or deficits would reduce funding flexibility, increase reliance on financing, and make growth investments harder to self-finance.
Margin And Cost PressureThe decline from earlier margin peaks suggests that profitability is exposed to cost inflation, investment-related depreciation, and mix or pricing pressure. These factors could limit the durability of recent improvement and constrain earnings growth even when revenue continues expanding.
Engineering Sales-cycle RiskLonger Engineering sales cycles and project phasing can delay order conversion and make this segment’s revenue less predictable. Although margins improved, continued timing pressure could weaken near-term growth, reduce operating leverage, and complicate execution across the broader portfolio.
Stevanato Group News
STVNN FAQ
What was Stevanato Group’s price range in the past 12 months?
Stevanato Group lowest stock price was $246.00 and its highest was $444.62 in the past 12 months.
What is Stevanato Group’s market cap?
Stevanato Group’s market cap is $99.39B.
When is Stevanato Group’s upcoming earnings report date?
Stevanato Group’s upcoming earnings report date is Nov 03, 2026 which is in 2 days.
How were Stevanato Group’s earnings last quarter?
Stevanato Group released its earnings results on Aug 04, 2026. The company reported $2.947 earnings per share for the quarter, beating the consensus estimate of $2.674 by $0.274.
Is Stevanato Group overvalued?
According to Wall Street analysts Stevanato Group’s price is currently Undervalued.
Does Stevanato Group pay dividends?
Stevanato Group does not currently pay dividends.
What is Stevanato Group’s EPS estimate?
Stevanato Group’s EPS estimate is 3.31.
How many shares outstanding does Stevanato Group have?
Stevanato Group has 49,709,717 shares outstanding.
What happened to Stevanato Group’s price movement after its last earnings report?
Stevanato Group reported an EPS of $2.947 in its last earnings report, beating expectations of $2.674. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Stevanato Group?
Currently, no hedge funds are holding shares in MX:STVNN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Stevanato Group Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$435.85 (50.29% Upside)
$435.85 (50.29% Upside)
Blogger Sentiment
Bearish
MX:STVNN Sentiment 67%
Sector Average 64%
Sector Average 64%
Insider Transactions
Sold Shares
Worth $8.7M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-22.01%
12-Months-Change
Fundamentals
Return on Equity
8.94%
Trailing 12-Months
Asset Growth
8.48%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Stevanato Group
Stevanato Group S.p.A. is dedicated to engineering, manufacturing, and distributing integrated solutions for the pharmaceutical and healthcare sectors. Its core offerings span a wide array of products, including containment solutions, drug delivery systems, and medical devices, alongside diagnostic and analytical support. The company also produces specialized machinery for tasks such as visual inspection, assembly, packaging, and glass formation. Established in 1949, the company's main operations are situated in Piombino Dese, Italy, functioning as a subsidiary of Stevanato Holding S.R.L.
STVNN Company Deck
STVNN Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a generally constructive operational and commercial story: top-line growth (8% y/y), strong expansion of high-value solutions (+16%) and significant adjusted EBITDA and margin improvement. The company announced an important commercial milestone (Alina approvals) and ongoing capacity build-outs that support mid- to long-term value capture in biologics. Offsetting these positives were one-time divestiture costs (EUR 12.2m), negative free cash flow in the quarter, elevated net debt, higher taxes, and caution around elongated sales cycles in Engineering. On balance, the highlights — recurring revenue growth, margin expansion, product approvals and clear capacity investments — outweigh the near-term lowlights tied largely to one-time items and measured execution/timing risks.View all MX:STVNN earnings summariesSTVNN Stock 12 Month Forecast
Average Price Target
$435.85
▲(50.29% Upside)
Technical Analysis
AptarGroup
―
Baxter International
―
Becton Dickinson
―
ICU Medical
―
West Pharmaceutical Services
―